Most AML-CEBPA cases are sporadic and harbor somatic CEBPA mutations, while approximately 10% of individuals inherit or develop de novo germline CEBPA mutations with predisposition to early-onset AML following acquisition of somatic CEBPA mutations [18]. This evidence concerns the gene CEBPA and acute myeloid leukemia.